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Background/Aims
ALADIN gene has been known to cause achalasia, alacrima, adrenal abnormalities and a progressive neurological syndrome. 
A considerable proportion of achalasia patients has been known to show alacrima (decreased secretion of tear). However, the 
genetic mechanism between achalasia and alacrima has not been defined yet. We postulated that ALADIN gene may be in-
volved in the occurrence of early-onset achalasia; thus, we investigated the correlation of ALADIN gene in early-onset achalasia 
patients. 
Methods
From 1989 to 2007, patients who were diagnosed as primary achalasia before age 35 were enrolled. All of the enrolled pa-
tients were asked for (1) blood sampling for DNA, (2) Shirmer test and (3) dysphagia questionnaires. 
Results
The ALADIN gene in exon 1, 2, 10, 11 and 12 from 19 patients was investigated (M:F = 12:7). The mean age of patients 
at diagnosis was 27 ± 5 (15-35) years old. Eight out of 19 (42%) showed alacrima by the positive Shirmer test. In spite of 
thorough exam in the genetic study, there was no definite abnormal genetic finding in this study. 
Conclusions
A considerable number of achalasia patients showed alacrima. Due to the limitation of this study, it is difficult to conclude 
that early-onset achalasia may have significant correlations with the ALADIN gene.
(J Neurogastroenterol Motil 2011;17:169-173)
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Figure. Depicted patients allocations.
Introduction
Achalasia has been known to be an inflammatory disease of 
unknown etiology characterized by esophageal aperistalsis and 
failure of lower esophageal sphincter (LES) relaxation due to loss 
of inhibitory nitrinergic neurons in the esophageal myenteric 
plexus.
1 Its pathophysiology has not been fully evaluated. How-
ever, infectious causes including Chagas’ disease and auto-
immune causes such as circulating autoantibodies against the 
myenteric plexus were suggested as the major culprits of acha-
lasia.
1-4 Triple A (Allgrove) syndrome has been characterized by 
achalasia, alacrima, and adrenocorticotrophic hormone (ACTH) 
resistant adrenal insufficiency.
5 This is a rare genetic disorder, 
with autosomal recessive inheritance, caused by genetic mutations 
on chromosome 12q13 (ALADIN or AAAS gene).
6 While a re-
cent report showed that 20% of achalasia patients showed defi-
cient secretion of tear, the relationship between the alacrima and 
achalasia has not been defined.
7 Recently, young male patients 
who exhibited achlasia and alacrima without other features of tri-
ple A syndrome were reported.
8 We postulated that there might 
be genetic variation regarding triple A syndrome and consid-
erable proportion of early-age onset achalasia might have correla-
tion with ALADIN gene. We aimed to investigate the relation-
ship between early-age onset achalasia and ALADIN gene. 
Materials and Methods
From 1989 to 2007, all of achalasia patients who were diag-
nosed as primary achalasia before age 35 in Asan Medical Center 
was asked to enroll this genetic study. By the review of medical 
record, a total of 44 patients was indicated to this study. A letter 
containing the detailed protocol and request for the participation 
in the study was sent to the patients. A total of 19 patients of pri-
mary achalasia answered the mail and allowed to enroll in this 
study. Finally a total of 19 patients (M:F = 12:7) of primary 
achalasia were enrolled. The mean age of patients at diagnosis 
was 27 ± 5 (15-35) years old. Most of them exhibited classic 
achalasia pattern by esophageal manometry, except for three pa-
tients showing vigorous achalasia pattern. All of them was ex-
plained with the aim and method of this study, and written con-
sent forms were given. All of the enrolled patients was asked for 
(1) blood sampling for DNA, (2) Shirmer test and (3) dysphagia 
questionnaires. This study was approved by the IRB of Asan 
Medical Center. This allocations are depicted in Figure. 
Blood Sampling for DNA 
We extracted genomic DNA from blood samples with in-
formed consent and performed linkage studies using micro-
satellite DNA available from the Genethon genetic map and 
Genome Database. Extraction of DNA from patients was per-
formed in two steps. First, DNA preparation was done from 
whole blood of each patient. White blood cell from whole blood 
was separated by erythrocyte lysis buffer. Genomic DNA from 
whole WBC was obtained using a genomic DNA purification kit 
(Wizard, Promega, Madison, WI, USA). The blood was stored 
at 4
oC. About 3-3.5 volume of EL buffer was added, mixed and 
chilled on ice for 20 minutes (RBC lysis). It was centrifuged at 
2,000 rpm for 10 minutes. Supernatant was discarded and wash-
ed with EL buffer (10 mL). Later, it was re-centrifuged at 2,000 
rpm for 10 minutes. Supernatant was discarded and suspended in 
200 μL phosphate buffered saline (PBS). Genomic DNA was 
extracted from whole WBC by following methods. 600 μL of nu-
cleic lysis solution was added to cell suspension, and then it was 
mixed gently by pipeting up and down three to five times to lyse 
the cells. The lysate was incubated at 65
oC for 20 minutes. To the 
room temperature sample, 200 μL of protein precipitation was 
added. Solution was vortex-mixed, followed by vigorous cen-
trifugation at high speed for 20 seconds, and samples were chilled 
on ice for 5 minutes. Centrifugation was done for 5 minutes at 
16,000 × g. The supernatant containing genomic DNA was 
carefully removed and it was transferred to 1.5 mL tube contain-
ing 600 μL of room-temperature isopropanol. The solution was 
gently mixed by inversion until the white thread-like strand of ge-
nomic DNA appeared. It was centrifuged for 1 minute at 16,000 
× g. The supernatant was carefully decanted and 600 μL of 70% 
ethanol was added at room temperature. It was centrifuged for 1 
minute at 16,000 × g. The pellet was dried at air for 10-15 
minutes. 100 μL of DNA rehydration solution was added and Genetic Correlation ALADIN Gene and Achalasia
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Table 1. Used Primer in DNA Test
Exon  Sequence Size  
Annealing
temperature
EX-1 F
EX-1 R
5'-GTC CGC ATA CGA ATC 
TAG CCC-3' 
5'-AGA CTC TGT GAC CCT 
GCC CCT-3' 
324 bp 57.6
oC 
62.5
oC 
EX-2 F
EX-2 R
5'- ATC TCT TAT ACT TAG 
CCC AGC-3' 
5'-GAA TAA AAG TCT TTT 
GAA GAA CAC-3'
328 bp 51.3
oC 
48.8
oC 
EX-10 F
EX-10 R
5'-AGA AAG GCA CTT AGC 
TCC TGG-3' 
5'-GAA TGC AGG AGG GAA 
AGT AGA-3' 
259 bp 56.8
oC 
54.1
oC 
EX-11 F
EX-11 R
5'-CTC TAC TTT CCC TCC 
TGC ATT CT-3' 
5'-TAT TTC CCT TTA TCC 
CTC AGA GC-3' 
247 bp 56.1
oC 
54.0
oC 
EX-12 F
EX-12 R
5'-CAG CTC TGA GGG ATA 
AAG GGA AA-3' 
5'-CAG GTT AGG AGA GTT 
TCA GTG TGG-3'
297 bp 56.4
oC 
57.0
oC 
DNA was rehydrated by incubating overnight at room temper-
ature or 4
oC. 
Polymerase chain reaction (PCR) was carried out in a total 
volume of 50 μL contained 20 ng of DNA, 0.2 mM dNTPs, 1 
U of Taq Gold polymerase, 1.5 mM MgCl2, 75 mM Tris HCl 
(pH 9.0), 20 mM (NH4)2SO4, 0.01% Tween-20 and 50 pmol of 
each primer. PCR was performed on a Perkin-Elmer 9700 ther-
mal cycler (Perkin Elmer, Applied Biosystems, Foster City, 
California, USA). The cycling consisted of denaturation at 94
oC 
for 10 minutes, followed by 30 cycles of 94
oC for 30 seconds, an-
nealing temperature for 30 seconds, and 72
oC for 35 seconds. 
Final extension at 72
oC for 10 minutes was carried out, and it was 
stored at 4
oC. PCR fragments were checked on a 1% agarose gel. 
PCR fragments were checked on a 1% agarose gel. Primers used 
in this study were exon 1, 2, 10, 11 and 12. The characteristics of 
each primer were described in Table 1. The PCR products were 
purified by using a Qiaquick purification kit (Qiagen, Hilden, 
Germany) and resuspended in 50 mL of deionized water. For 
each exon, 100 ng of amplified product was sequenced using for-
ward and reverse primers and the BigDye Terminator cycle se-
quencing kit (Perkin Elmer). Sequencing was performed on an 
ABI377 automated sequencer. Alignment and analysis were car-
ried out with Sequence Navigator (Perkin Elmer). 
Shirmer Test
The Shirmer I test was undergone in all of the enrolled 
patients. The Shirmer test without anesthesia (Shirmer I test) is 
known to be a well-standardized test that is currently performed 
with the patient’s eyes closed.
9,10 This is a test to estimate tear re-
flex by insertion of a filter paper (5 × 35 mm, Color Bar
TM, 
EagleVision Co, Memphis, TN, USA) into the conjunctival sac. 
All patients were asked not to take any medications which can af-
fect the result of Shirmer test including anti-histamine, or com-
mon cold drugs containing anti-histamine or decongestants be-
fore 7 days of the Shirmer test. Achalasia patients with combined 
rheumatologic disorders which can affect the result of Shirmer 
test including Sjögren’s disease were excluded. A Shirmer paper 
strip folded at 5 mm from one end was inserted over the lower lid 
margin, midway between the middle and outer third. The patient 
was asked to close eye. After 5 minutes, the interpretation of re-
sult was done. The cut-off value < 10 mm was determined as de-
creased secretion of tear.
10 If the result of 1 eye was abnormal, the 
patient was regarded to have abnormally decreased secretion of 
tear. 
Dysphagia Questionnaire
All of enrolled patients were asked with dysphagia ques-
tionnaire (Asan dysphagia questionnaire) regarding their symp-
toms associated with dysphagia. Questionnaires consisted of du-
ration of dysphagia, the age of first diagnosis, family history of 
dysphagia and number of balloon dilatation. 
Statistical Methods
The Mann-Whitney U test was utilized due to the skewed 
and relatively small number of samples used to compare the nu-
merical data. The chi-square test or the Fisher’s exact test was 
used to analyze non-numerical data. A P-value < 0.050 was re-
garded as statistically significant. All analyses were performed 
with SPSS 14.0 (SPSS Inc, Chicago, IL, USA) for Windows.
Results
Shirmer Test
Eight out of 19 (42%) showed alacrima by the positive 
Shirmer test. Patients were categorized into positive and negative 
Shirmer test groups. The characteristics of each group were com-
pared (Table 2). However, there were no significant differences Kee Wook Jung, et al
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Table 2. Results of the Shirmer Test in Early-Age Onset Achalasia
Variables
Alacrima
(n = 8)
Normal 
secretion 
of tear (n = 11)
P-value
Sex (M:F) 6:2 6:5    0.362
Age at first symptom
a 28 (23-35) 28 (13-30)   0.679
Age at first diagnosis
a 26 (22-35) 26 (15-33)   0.300
Shirmer test
Right eye (mm)
a
Left eye (mm)
a
4.0 (0-8)
6.5 (0-8)
25.0 (10-35)
25.0 (12-35)
<0.003
<0.001
Vigorous achalasia (n) 1 2     0.738
Disease duration (yr)
a 3 (1-15) 3 (1-16)     0.430
No. of balloon dilatation
a 1 (0-3) 1 (1-2)     0.957
Family history of dysphagia (n) 1 1     0.811
aData are presented as median (range).
between them except for the result of Shirmer test.  
DNA Analysis
We investigated the ALADIN gene in exon 1, 2, 10, 11 and 
12 from 19 patients (M:F = 12:7). At first, the doubtful se-
quences, the majority of which were A insertions, were only 
found between 40th and 41st location in the exon 1 throughout 
the ALADIN gene among 4 out of 19 enrolled patients. For fur-
ther confirmation of doubtful sequence, additional DNA se-
quence analyses were performed. However, the previously identi-
fied inserted A was not a real finding. For that reason, in this 
study, the genetic mutations were not considered to be present. 
Discussion
Early-onset achalasia patients exhibited considerable pro-
portion of alacrima. However, the reason of alacrima was un-
certain by this study. The overlooking in the sample volume limit 
of consented patients as well as their number may cause to gain 
undesirable results since all designed primers had not been ap-
plied even. If volume and number of samples were prepared 
enough, more chances could be made to elucidate genetic alter-
ations in the achalasia patients by using unused primers.
By our study, considerable proportion of early-onset acha-
lasia patients (42%) exhibited alacrima. In the study of Verma et 
al,
7 4 out of 20 achalasia patients (20%) exhibited alacrima. 
Verma’s study enrolled the achalasia patients of the age from 21 
to 84 years old. However, our study just enrolled the early-age 
onset achalasia patients whose onset age was before 35 years old. 
By this result, we postulated that younger achalasia patients 
might have more possibility of the genetic association with 
ALADIN gene. 
The defect of AAAS gene might create the symptoms of alac-
rima, achalasia and adrenal insufficiency. However, late onset tri-
ple A syndrome only was reported as a case report in which only 
one or two of these manifestations were shown such as alacrima 
and achalasia without adrenal insufficiency. Therefore, we postu-
lated that early onset achalasia patients could have enough reason 
that those symptoms were caused by AAAS genetic defect.
We tried to find the genetic association between ALADIN 
gene and achalasia with alacrima. However, the result was 
uncertain. We postulated that there might be 2 hypotheses. First, 
achalasia and alacrima of patients might have no correlation be-
tween them. Therefore, the etiology of achalasia and alacrima 
might be different from the beginning. Second, another genetic 
mechanism might reside in both achalalasia and alacrima. Due to 
limitation of the number of patients and budget, we could not 
evaluate the full sequence of enrolled patients. If more available 
patients could be analyzed in this study, we could find more val-
uable results from the achalasia patients. 
We found the considerable proportion of early-age onset 
achalasia had alacrima. Alacrima could be manifested by the ia-
trogenic causes including anti-histamine medication. However, 
all of the enrolled patients refrained from the medications causing 
decreased secretion of tear. Connective tissue disorders including 
Sjögren’s syndrome could manifest alacrima. However, all the 
enrolled patients were negative from the symptoms and signs of 
connective tissue disorders. When compared from the previous 
report of alacrima in 20% of achalasia patients from young to old 
age, our study based on the early-age onset achalasia with the on-
set age below 35 years old might have more proportion of 
alacrima.
7 The mean age of patient taking Shirmer test was 32 ± 
6 years old. Of the relatively young achalasia patients, 42% 
showed decreased secretion of tear. Older patients usually show 
decreased secretion of tear or saliva due to degenerative change of 
secretory gland. The exact mechanism is not clear. If the 
ALADIN gene has no definite correlation with alacrima, further 
studies regarding the relationship between them might be needed.
We used the primers in exon 1, 2, 10, 11 and 12, which were 
selected by the reference of other group from 19 patients to inves-
tigate the mutations.
11 According to the other group’s physical 
map of the triple-A critical region,
12 the disease genes were pre-
sumed to be confined in the chromosome 12q13,
13,14 where 16 
exons are included. Although present work does not show any Genetic Correlation ALADIN Gene and Achalasia
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mutations in 16 Korean patients, the possibility of genetic correla-
tion should not be easily ignored since the number of patients in 
present work was not large and another possibility of mutation 
detection in other exons by using possible primers (supplemen-
tary data
12) is still remained as well. Unfortunately, we could not 
find any definite Triple A syndrome patients with ACTH in-
sensitivity by symptoms alone. Because of limitation of finance 
and difficulty in sampling regarding ACTH insensitivity, we 
could not gather sufficient data to define the relationship between 
ACTH insensitivity and our cohort patients. However, based on 
the previously published papers,
8,15 those patients could show the 
ACTH insensitivity.
In conclusion, the considerable proportion of early-age onset 
achalasia manifested alacrima. The genetic association between 
these patients and ALADIN gene was not clear. However, fur-
ther evaluations might be needed to demonstrate clinical correla-
tions with these data. 
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